

November 7, 2005

Contact Information:
Corporate Communications
Astellas Pharma Inc.
Phone: +81-3-3244-3201

**NOTICE REGARDING ACQUISITION
OF THE COMPANY'S OWN SHARES**

(Share buyback pursuant to the provisions of Article 211-3, paragraph 1, item 2 of the
Commercial Code of Japan)

Japan, November 7, 2005 – Astellas Pharma Inc. (“the Company”, headquarters: Tokyo, president and CEO: Toichi Takenaka) announced that at the meeting of the Board of Directors held today, a resolution was adopted that the Company will acquire its own shares pursuant to the provisions of Article 211-3, paragraph 1, item 2 of the Commercial Code of Japan:

Particulars

1. Reasons for the Acquisition of its own shares

The Company intends to acquire its own shares as a part of flexible financial policies and return to shareholders.

2. Contents of Acquisition

- | | |
|--|--|
| (1) Class of shares to be acquired: | Common stock of the Company |
| (2) Total number of shares to be acquired: | 6,000 thousand shares (Maximum)
(The percentage compared to the total number of shares issued: 1.05%) |
| (3) Aggregate amount of acquisition cost: | 27,000 million yen (Maximum) |
| (4) Period of acquisition: | From November 8, 2005 to December 8, 2005 |

#####